Trianglecemiplimab+fianlimab (NCT07179315)
cemiplimab+fianlimab trial for Head and Neck Cancer (NCT07179315). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with HPV-positive oropharyngeal squamous cancer after definitive treatment, with no definite clinical or imaging disease but NavDx-confirmed HPV tumor DNA. Treatment must have finished at least one month earlier.
The idea: cemiplimab blocks the PD1 immune brake; fianlimab blocks LAG3. Patients are randomly assigned cemiplimab alone or both drugs for one year. Researchers compare recurrence-free survival and safety. PDL1 testing is required for stratification, without a specified positivity cutoff.
This phase 2 study plans 68 patients. Ari Rosenberg leads at University of Chicago, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.